A live blog published at the 22nd International Network for Psychiatric Nursing Research conference in Nottingham.
Written by John Baker, Lucy Brazener, Wendy Cross, Vanessa Garrity, Andrew Grundy, Cher Hallett, Ben Hannigan, Elaine Hanzak and Alan Simpson.
[read the full story...]
Alex Langford explores the emerging findings from a recent meta-analysis looking at the efficacy and safety of antidepressants added to antipsychotics for people with schizophrenia and schizophrenia-like psychosis.
[read the full story...]
Paul Christiansen presents the results of the EAGLES RCT into the neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patches in smokers with and without psychiatric disorders.
[read the full story...]
Edzard Ernst shines a light on the unfounded claims presented in a meta-analysis published today on acupuncture for amnestic mild cognitive impairment.
[read the full story...]
Murtada Alsaif summarises a recent 4-week long phase II randomised controlled trial of ITI-007 for the treatment of schizophrenia, which contains some positive results for this novel intervention.
[read the full story...]
Alison Faulkner reflects on the findings of a qualitative study from New Zealand that explores users’ diverse experiences of taking antidepressants.
[read the full story...]
Sarah Knowles considers the findings of a recent systematic review looking at the effectiveness of prompts to promote engagement with digital interventions.
[read the full story...]
Samuele Cortese considers the findings of a recent nationwide self controlled case series study of the cardiovascular safety of methylphenidate use in children and young people with ADHD.
[read the full story...]
Matt Field presents new evidence on the risks and benefits of nalmefene in the treatment of adult alcohol dependence, which casts further doubt over the controversial recommendations made by NICE and the European Medicines Agency.
[read the full story...]
Tracey Roberts summarises a recent RCT of the efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia.
[read the full story...]
